Beyond the psychedelic hype: Exploring the persistence of the neoliberal paradigm
James R Davies, Brian A. Pace, Neşe Devenot
Journal of Psychedelic Studies September 21, 2023 DOI: 10.1556/2054.2023.00273 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Commodification Mental distress Neoliberalism international relations Medicalization Mental health Status quo Mental illness Ideology Politics Precarity Criminology Environmental ethics Political economy |
| Citations | 29 |
| Key points | Argues that the psychedelic industry's current instantiation aligns with and upholds key facets of neoliberal ideology, rather than disrupting the psychopharmaceutical status quo. |
Abstract
Abstract Background and Aims Advocates of psychedelic medicine have positioned psychedelics as a novel therapeutic intervention that will solve the mental health crisis by liberating individuals from their entrenched habits and limiting beliefs. Despite claims for novelty, the psychedelics industry is engaging in the same profit-oriented approaches that contributed to poor clinical outcomes with SSRIs and other earlier pharmaceuticals, which threatens to undermine their purported clinical benefits.
Methods: We present evidence that the liberatory rhetoric of psychedelic medicalization promotes neoliberal, individualised treatments for distress, which distracts from collective efforts to address root causes of suffering through systemic change. Drawing examples from the psychedelics industry, we illustrate how the discourse of psychedelic medicalisation subjects socially-determined distress to psychotropic intervention through the mechanisms of depoliticisation, productivisation, pathologisation, commodification, and de-collectivisation.
Results: Rather than disrupting or subverting the psychopharmaceutical status quo, the psychedelic industry's current instantiation aligns with and upholds key facets of neoliberal ideology by adhering to the same facilitative mechanisms that scholars identified in the antidepressant industry. We identify these common mechanisms in examples unique to the psychedelics industry, including the search for psychedelic analogues and political lobbying to reschedule psychedelics.
Conclusion: We demonstrate how a neoliberal mental health paradigm that individualises and interiorizes mental distress cannot meaningfully resolve suffering with ubiquitous origins in the current sociopolitical environment, which is characterised by inequality, precarity, exploitation, and ecological collapse. As a result, psychedelics must decouple from neoliberal incentives, and demonstrate efficacy, if they are to facilitate durable improvements in well-being and prosocial outcomes.